Chemotherapy in the management of advanced cutaneous malignant melanoma

Clinics in Dermatology

Volumn 31, Issue 3, 2013, Pages 290-297

  Luke, Jason J ^a,b   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; B RAF KINASE; BEVACIZUMAB; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; FOTEMUSTINE; INTERLEUKIN 2; IPILIMUMAB; LOMEGUATRIB; LOMUSTINE; OBLIMERSEN; OLAPARIB; PACLITAXEL; PLATINUM COMPLEX; SORAFENIB; TAMOXIFEN; TEMOZOLOMIDE; VELIPARIB; VEMURAFENIB; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BRAF GENE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL DECISION MAKING; COLITIS; CUTANEOUS MELANOMA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL TOXICITY; GENE MUTATION; GLIOBLASTOMA; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUROPATHY; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMIC DISEASE; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOTHERAPY; MELANOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84876714102     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2012.08.016     Document Type: Article

References (79)

1. Bajetta E., Del Vecchio M., Bernard-Marty C., et al. Metastatic melanoma: chemotherapy. Semin Oncol 2002, 29:427-445.
2. Li Y., McClay E.F. Systemic chemotherapy for the treatment of metastatic melanoma. Semin Oncol 2002, 29:413-426.
3. Crosby T., Fish R., Coles B., Mason M.D. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev 2000, 2:CD001215.
4. Middleton M.R., Grob J.J., Aaronson N., et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000, 18:158-166.
5. Patel P.M., Suciu S., Mortier L., et al. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer 2011, 47:1476-1483.
6. Hegi M.E., Diserens A.-C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
7. Boeckmann L., Nickel A.C., Kuschal C., et al. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution. Melanoma Res 2011, 21:206-216.
8. Wedge S.R., Porteous J.K., Newlands E.S. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol 1997, 40:266-272.
9. Hassel J.C., Sucker A., Edler L., et al. MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer 2010, 103:820-826.
10. Ranson M., Middleton M.R., Bridgewater J., et al. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2006, 12:1577-1584.
11. Ranson M., Hersey P., Thompson D., et al. Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 2007, 25:2540-2545.
12. Rietschel P., Wolchok J.D., Krown S., et al. Phase II study of extended-dose temozolomide in patients with melanoma. J Clin Oncol 2008, 26:2299-2304.
13. Neyns B., Tosoni A., Hwu W.J., Reardon D.A. Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects. Cancer 2010, 116:2868-2877.
14. Ghiringhelli F., Menard C., Puig P.E., et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007, 56:641-648.
15. Banissi C., Ghiringhelli F., Chen L., Carpentier A.F. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 2009, 58:1627-1634.
16. Su Y.B., Sohn S., Krown S.E., et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004, 22:610-616.
17. Antony P.A., Piccirillo C.A., Akpinarli A., et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005, 174:2591-2601.
18. Gattinoni L., Finkelstein S.E., Klebanoff C.A., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med 2005, 202:907-912.
19. Atkins M. The role of cytotoxic chemotherapeutic agents either alone or in combination with biological response modifiers. Molecular diagnosis, prevention and therapy of melanoma 1997, 219. Marcel Dekker, New York. J. Kirkwood (Ed.).
20. Houghton A., Legha S., Bajorin D. Chemotherapy for metastatic melanoma. Cutaneous melanoma 1992, 498. Lippincott Williams & Wilkins, Hagerstown (Md). C. Balch, A. Houghton, Milton (Eds.).
21. Avril M.F., Aamdal S., Grob J.J., et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004, 22:1118-1125.
22. Quagliana J.M., Stephens R.L., Baker L.H., Costanzi J.J. Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study. J Clin Oncol 1984, 2:316-319.
23. Nelimark R.A., Peterson B.A., Vosika G.J., Conroy J.A. Vindesine for metastatic malignant melanoma. A phase II trial. Am J Clin Oncol 1983, 6:561-564.
24. Bedikian A.Y., Papadopoulos N.E., Kim K.B., et al. A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma. Melanoma Res 2008, 18:400-404.
25. Whitehead R.P., Moon J., McCachren S.S., et al. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study. Cancer 2004, 100:1699-1704.
26. Jimeno A., Hitt R., Quintela-Fandino M., Cortes-Funes H. Phase II trial of vinorelbine tartrate in patients with treatment-naive metastatic melanoma. Anticancer Drugs 2005, 16:53-57.
27. Einzig A.I., Hochster H., Wiernik P.H., et al. A phase II study of taxol in patients with malignant melanoma. Invest New Drugs 1991, 9:59-64.
28. Aamdal S., Wolff I., Kaplan S., et al. Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer 1994, 30A:1061-1064.
29. Homsi J., Bedikian A.Y., Kim K.B., et al. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res 2009, 19:238-242.
30. Ibrahim N.K., Desai N., Legha S., et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002, 8:1038-1044.
31. Hersh E.M., O'Day S.J., Ribas A., et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer 2010, 116:155-163.
32. Evans L.M., Casper E.S., Rosenbluth R. Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep 1987, 71:171-172.
33. Legha S.S., Ring S., Papadopoulos N., Plager C., Chawla S., Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989, 64:2024-2029.
34. McClay E.F., Mastrangelo M.J., Berd D., Bellet R.E. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 1992, 50:553-556.
35. Margolin K.A., Liu P.Y., Flaherty L.E., et al. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. J Clin Oncol 1998, 16:664-669.
36. Rusthoven J.J., Quirt I.C., Iscoe N.A., et al. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996, 14:2083-2090.
37. Creagan E.T., Suman V.J., Dalton R.J., et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol 1999, 17:1884-1890.
38. Bafaloukos D., Gogas H., Georgoulias V., et al. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. J Clin Oncol 2002, 20:420-425.
39. Chapman P.B., Einhorn L.H., Meyers M.L., et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999, 17:2745-2751.
40. Kottschade L.A., Suman V.J., Amatruda T., et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1). Cancer 2011, 117:1704-1710.
41. Vuoristo M.S., Hahka-Kemppinen M., Parvinen L.M., et al. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. Melanoma Res 2005, 15:291-296.
42. Legha S.S., Ring S., Bedikian A., et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996, 7:827-835.
43. Legha S.S., Ring S., Eton O., et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998, 16:1752-1759.
44. Eton O., Legha S.S., Bedikian A.Y., et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002, 20:2045-2052.
45. Atkins M.B., Hsu J., Lee S., et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008, 26:5748-5754.
46. Bajetta E., Del Vecchio M., Nova P., et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 2006, 17:571-577.
47. Keilholz U., Punt C.J., Gore M., et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005, 23:6747-6755.
48. Ridolfi R., Chiarion-Sileni V., Guida M., et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002, 20:1600-1607.
49. Ives N.J., Stowe R.L., Lorigan P., Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007, 25:5426-5434.
50. McDermott D.F., Atkins M.B. More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma. J Clin Oncol 2007, 25:3791-3793.
51. Tarhini A.A., Kirkwood J.M., Gooding W.E., Cai C., Agarwala S.S. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol 2007, 25:3802-3807.
52. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
53. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
54. Eigentler T.K., Weide B., de Braud F., et al. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res 2011, 17:7732-7742.
55. O'Day S., Pavlick A., Loquai C., et al. A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer 2011, 105:346-352.
56. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
57. Perez D.G., Suman V.J., Fitch T.R., et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 2009, 115:119-127.
58. Vihinen P.P., Hernberg M., Vuoristo M.S., et al. A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma. Melanoma Res 2010, 20:318-325.
59. Del Vecchio M., Mortarini R., Canova S., et al. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res 2010, 16:5862-5872.
60. Boasberg P., Cruickshank S., Hamid O., O'Day S., Weber R., Spitler L. Nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable stage III and IV melanoma. J Clin Oncol 2009, 27:476s. [abstr 9061].
61. Hauschild A., Agarwala S.S., Trefzer U., et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009, 27:2823-2830.
62. Soengas M.S., Lowe S.W. Apoptosis and melanoma chemoresistance. Oncogene 2003, 22:3138-3151.
63. Bedikian A.Y., Millward M., Pehamberger H., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006, 24:4738-4745.
64. Agarwala S.S., Keilholz U., Gilles E., et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer 2009, 45:1807-1814.
65. Palma J.P., Wang Y.C., Rodriguez L.E., et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 2009, 15:7277-7290.
66. Sinnberg T., Lasithiotakis K., Niessner H., et al. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol 2009, 129:1500-1515.
67. Thallinger C., Werzowa J., Poeppl W., et al. Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice. J Invest Dermatol 2007, 127:2411-2417.
68. Pinnix C.C., Lee J.T., Liu Z.J., et al. Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res 2009, 69:5312-5320.
69. Panelos J., Massi D. Emerging role of Notch signaling in epidermal differentiation and skin cancer. Cancer Biol Ther 2009, 8:1986-1993.
70. Li C., Chi S., Xie J. Hedgehog signaling in skin cancers. Cell Signal 2011, 23:1235-1243.
71. Zhang J.P., Qin H.Y., Wang L., et al. Overexpression of Notch ligand Dll1 in B16 melanoma cells leads to reduced tumor growth due to attenuated vascularization. Cancer Lett 2011, 309:220-227.
72. Huynh C., Poliseno L., Segura M.F., et al. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PLoS One 2011, 6:e25264.
73. Meng R.D., Shelton C.C., Li Y.M., et al. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 2009, 69:573-582.
74. Eigentler T.K., Radny P., Hauschild A., et al. Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. Melanoma Res 2008, 18:353-358.
75. Kudriavtsev D.V., Kudriavtseva G.T., Mardynskii Iu.S. Adjuvant chemotherapy as a component of complex treatment for skin melanoma. Vopr Onkologii 2008, 54:170-177. [Russian].
76. Saba H.I., Cruse C.W., Wells K.E., Klein C.J., Reintgen D.S. Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Ann Plast Surg 1992, 28:60-64.
77. Lewis K.D., Robinson W.A., McCarter M., et al. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma. J Clin Oncol 2006, 24:3157-3163.
78. Buzaid A.C., Colome M., Bedikian A., et al. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res 1998, 8:549-556.
79. Shah G.D., Socci N.D., Gold J.S., et al. Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. Ann Oncol 2010, 21:1718-1722.